Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697307 | 0.87 | SYK (0.32) | SYKPDPK1 | |
| SCHEMBL5239139 | 0.81 | MAPKAPK2 (0.31) | — | |
| SCHEMBL4788793 | 0.75 | SYK (0.34) | SYKJAK3BTK | |
| SCHEMBL22485954 | 0.74 | CYP11B2 (0.33) | PDPK1GPR119 | |
| SCHEMBL26647052 | 0.70 | CCR4 (0.32) | PDPK1 | |
| SCHEMBL13058645 | 0.69 | CDK1 (0.36) | — | |
| SCHEMBL25263548 | 0.69 | GPR119 (0.41) | PDPK1GPR119 | |
| SCHEMBL13195655 | 0.69 | USP30 (0.32) | PDPK1 | |
| SCHEMBL22932340 | 0.69 | SYK (0.46) | SYKPDPK1GPR119JAK3BTK | |
| SCHEMBL31349701 | 0.69 | USP30 (0.32) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793817-A4 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS INC (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| EP-1793817-A2 | METHODS OF TREATING A DISORDER | Elixir Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| WO-2006031894-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1351959-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | SYK 2916/4885PDPK1 2954/4885GPR119 925/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | SYK 2559/4885PDPK1 2777/4885GPR119 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.